The effects of
1-(biphenyl-4-ylmethyl)-1,2,3,4-tetrahydroisoquinoline-6,7-diol (EDL-155) on the growth of
glioma was tested in vitro and in vivo. Normal cultured rat astrocytes and C6 rat
glioma were used as a differential screen to test the effects of
EDL-155. The compound was preferentially cytotoxic for C6
glioma (EC50=1.5 micromol/l) relative to cultured neonatal astrocytes (EC50=27.4 micromol/l). When compared with a standard chemotherapeutic agent,
carmustine (1,3-bis[2-chloroethyl]-1-nitrosourea), or
temozolomide,
EDL-155 was more selective and more potent in our differential tissue culture assay. The effect of
EDL-155 was also tested in an animal model in which C6
glioma was transplanted into the brains of Sprague-Dawley rats.
EDL-155 was delivered directly onto the
tumor by an osmotic minipump directly into the brain or by
intraperitoneal injection. Animals treated with
EDL-155 had significantly smaller
tumors than did control animals treated with carrier
solution. We observed anatomical changes in cultured
glioma cells treated with
EDL-155 that were consistent with selective destruction of mitochondria and the induction of autophagy. These changes were not observed in normal astrocytes cultured from rat pups. The selective killing of
glioma in tissue culture and in the rat brain models indicates that
EDL-155 has potential therapeutic value in treating this type of
brain cancer.